Rocket Pharmaceuticals insider to sell 12,253 shares

Rocket Pharmaceuticals insider Martin Wilson has filed a notice to sell 12,253 common shares.

Rhea-AI Filing Summary

Rocket Pharmaceuticals insider Martin Wilson has filed a notice to sell 12,253 common shares. The shares were recently acquired through restricted stock vesting on 02/11/2026 as compensation from the issuer. The planned sale through Fidelity Brokerage Services LLC has an aggregate market value of $40,583.16 and is listed for trading on NASDAQ, with an approximate sale date of 02/13/2026. The filing notes that 108,222,228 common shares were outstanding, and also discloses a prior sale of 1,646 shares for $4,909.69 on 11/18/2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the latest Form 144 filing for RCKT disclose?

The filing shows insider Martin Wilson plans to sell 12,253 Rocket Pharmaceuticals common shares. These were acquired via restricted stock vesting and will be sold through Fidelity Brokerage Services on NASDAQ, with an approximate sale date of February 13, 2026.

How many RCKT shares is Martin Wilson planning to sell under this notice?

Martin Wilson plans to sell 12,253 Rocket Pharmaceuticals common shares. The aggregate market value of this planned sale is $40,583.16, based on the figures in the notice, and the transaction is expected to occur on or around February 13, 2026.

How did the RCKT shares in this Form 144 filing be acquired?

The 12,253 Rocket Pharmaceuticals shares were acquired through restricted stock vesting on February 11, 2026. The issuer granted the shares as compensation, meaning no cash purchase was involved at acquisition according to the filing details.

What prior RCKT share sales by this insider are disclosed?

The filing reports that Martin Wilson previously sold 1,646 Rocket Pharmaceuticals common shares on November 18, 2025. Those sales generated gross proceeds of $4,909.69, and are disclosed as required for transactions during the past three months.

Which broker and exchange are involved in this RCKT share sale?

The planned Rocket Pharmaceuticals share sale will be executed through Fidelity Brokerage Services LLC. The notice lists NASDAQ as the securities exchange where the 12,253 common shares are expected to be sold, with an approximate sale date of February 13, 2026.

How many Rocket Pharmaceuticals shares were outstanding in this filing?

The notice states that 108,222,228 Rocket Pharmaceuticals common shares were outstanding. This figure provides context for the planned sale of 12,253 shares, which represents a small portion of the total shares reported as outstanding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 04:31 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001704342
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ROCKET PHARMACEUTICALS, INC.
SEC File Number	001-36829
Address of Issuer	350 FIFTH AVENUE SUITE 7530 NEW YORK NEW YORK 10118
Phone	646-440-9100
Name of Person for Whose Account the Securities are To Be Sold	Wilson Martin
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	12253	40583.16	108222228	02/13/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/11/2026	Restricted Stock Vesting	Issuer			12253	02/11/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Martin Wilson 9 Cedarbrook Drive Cranbury NJ 08512	Common	11/18/2025	1646	4909.69

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	02/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jessica Spraker, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Martin Wilson.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)